When was Ability founded?

Ability was founded in 2023 and raised its 1st funding round within a year of its incorporation.

Where is Ability located?

Ability is headquartered in Montreal, Canada.

How many employees does Ability have?

As of Jul 31, 2026, the latest employee count at Ability is 31.

Is Ability a funded company?

Ability is a funded company, having raised a total of $30M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 06, 2023.

When was the latest funding round of Ability?

Ability's latest funding was a $***** Seed round on Jun 18, 2024, with participation from 6 investors.

Where does Ability rank among its competitors?

Ability ranks 215th amongst 3476 active competitors, of which 1181 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Ability?

Ability's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Ability - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of modulating biotherapeutics to address cancer and autoimmune diseases. It has AbiLeap discovery engine that combines continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies across cancer and autoimmune applications. The pipeline includes Leap 1121 for auti-immune disease, Leap 1009 and 1030 for solid tumors.

Website: www.ability.bio/en/
Email ID: *****@ability.bio

Key Metrics

Founded Year

2023

Location

Montreal, Canada

Stage

Seed

Total Funding

$30M in 2 rounds

Latest Funding Round

Seed, Jun 18, 2024, $*****

Investors

Amplitude & 6 more

Ranked

215^th among 3476 active competitors

Employee Count

31 as on Jul 31, 2026

Similar Companies

BeiGene & 5744 more

View Ability's full profile

Ability has raised a total funding of $30M over 2 rounds. Its first funding round was on Dec 06, 2023. Its latest funding round was a Seed round on Jun 18, 2024 for $*****. 6 investors participated in its latest round. Ability has 7 institutional investors.

Here is the list of recent funding rounds of Ability:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 18, 2024	2476061	Seed	5402385	1772958	6858347	2379693
Dec 06, 2023	2077861	Seed	6423122	1840348	Amplitude	Fonds de solidarite FTQ & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Ability's funding rounds and investors

The founders of Ability is Giles Day. Giles Day is the CEO of Ability.

Here are the details of Ability's key team members:

Giles Day: Co-Founder & CEO of Ability and founder of 1 other company.

View details of Ability's Founder profiles and Board Members

Ability's employee count trend

Ability has 31 employees as of Jul 26. Here is Ability's employee count trend over the years:

Uncover Ability's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ability include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Ability, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
215th	Ability 2023, Montreal (Canada), Seed	Developer of modulating biotherapeutics to address cancer and autoimmune diseases	$30M	Amplitude, Alexandria & 5 others	59/100